Research & Educational Use Only. This protocol guide is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before beginning any research protocol. Path To Peptides does not sell compounds and is not responsible for individual use decisions.
GLP-1 Receptor Agonist
Evidence Grade: A (FDA-Approved Analog)
Semaglutide Protocol Guide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist researched for its role in metabolic regulation, appetite modulation, and glycemic control. This protocol guide covers reconstitution, titrated dosing schedules, subcutaneous administration technique, expected weekly timelines, side effect management, and recommended blood work panels for research monitoring.
Protocol Overview
- Compound
- Semaglutide
- Category
- GLP-1 Receptor Agonist
- Mechanism
- Binds GLP-1 receptors, enhancing insulin secretion, suppressing glucagon, slowing gastric emptying, and modulating appetite signaling in the hypothalamus
- Molecular Weight
- 4,113.58 Da
- Half-Life
- ~168 hours (7 days)
- Vial Size
- 5mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- Once weekly
- Cycle Length
- 12-16+ weeks (with titration)
Dosing Protocol
Semaglutide follows a slow titration schedule to minimize gastrointestinal side effects. Each dose level is maintained for 4 weeks before escalating.
| Phase | Weeks | Dose | Frequency | Route |
|---|---|---|---|---|
| Titration 1 | 1-4 | 0.25 mg | Once weekly | Subcutaneous |
| Titration 2 | 5-8 | 0.5 mg | Once weekly | Subcutaneous |
| Titration 3 | 9-12 | 1.0 mg | Once weekly | Subcutaneous |
| Titration 4 | 13-16 | 1.7 mg | Once weekly | Subcutaneous |
| Maintenance | 17+ | 2.4 mg | Once weekly | Subcutaneous |
Note: Not all subjects will titrate to the maximum dose. Dose escalation should be guided by tolerability and research objectives. If significant GI side effects occur, remain at the current dose for an additional 4 weeks before escalating.
Reconstitution Instructions
Materials Needed
- Semaglutide 5mg lyophilized vial
- Bacteriostatic water (BAC water)
- 3mL syringe with 18-20ga needle (for reconstitution)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol swab
- Draw 2mL bacteriostatic water into syringe
- Insert needle and slowly release water down the vial wall
- Gently swirl - never shake the vial
- Allow to sit until fully dissolved (5-10 minutes)
- Final concentration: 2.5 mg/mL (0.25mg per 10 units on insulin syringe)
| Dose | Volume (2mL reconstitution) | Insulin Syringe Units |
|---|---|---|
| 0.25 mg | 0.10 mL | 10 units |
| 0.5 mg | 0.20 mL | 20 units |
| 1.0 mg | 0.40 mL | 40 units |
| 1.7 mg | 0.68 mL | 68 units |
| 2.4 mg | 0.96 mL | 96 units |
Administration Guide
Injection Sites
- Abdomen: 2 inches from navel (preferred)
- Thigh: Front/outer middle third
- Upper arm: Back of arm (if administered by another person)
Rotate injection sites to prevent lipodystrophy.
Timing & Storage
- Day/Time: Choose one day per week, same time each day
- With food: Can be administered regardless of meals
- Storage (unreconstituted): Refrigerate 2-8°C or room temp up to 30 days
- Storage (reconstituted): Refrigerate 2-8°C, use within 30 days
- Protect from light and heat
Expected Timeline
Week 1-2
Initial adaptation period. Mild appetite reduction may begin. Some subjects report mild nausea as the body adjusts to GLP-1 receptor activation.
Week 3-4
Appetite suppression becomes more noticeable. Early changes in fasting glucose may appear. GI side effects typically begin to subside.
Week 5-8
At 0.5mg dose, more consistent appetite modulation. Subjects in clinical research showed measurable metabolic changes. Body composition changes may begin.
Week 9-12
At 1.0mg dose, significant appetite regulation observed. Lipid panel and glycemic markers often show improvement in research settings. Noticeable body composition changes reported.
Week 13-16+
Higher doses (1.7-2.4mg) produce peak effects. Sustained metabolic improvements. Long-term cardiovascular biomarker benefits observed in clinical trials (SELECT trial).
Side Effects & Monitoring
Common Side Effects
- Nausea (most common, usually transient)
- Diarrhea or constipation
- Abdominal discomfort or bloating
- Decreased appetite (intended effect)
- Fatigue during initial titration
- Injection site reactions (redness, mild swelling)
- Headache
Serious Concerns (Discontinue & Seek Medical Attention)
- Severe or persistent abdominal pain (pancreatitis risk)
- Signs of allergic reaction (rash, swelling, difficulty breathing)
- Significant hypoglycemia symptoms
- Gallbladder issues (pain in upper right abdomen)
- Vision changes
- Thyroid nodule or neck swelling
Contraindications
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Severe gastrointestinal disease
- Pregnancy or breastfeeding
Stacking Recommendations
Semaglutide is commonly researched alongside the following compounds for synergistic metabolic and body composition outcomes:
Compatible Compounds
- BPC-157: GI-protective properties may help manage GI side effects
- Tesamorelin: GH-releasing for visceral fat reduction synergy
- AOD-9604: Fat metabolism fragment, complementary mechanism
- 5-Amino-1MQ: NNMT inhibitor for metabolic support
- MOTS-C: Mitochondrial peptide for metabolic optimization
Stacking Notes
- Avoid stacking with other GLP-1 agonists (liraglutide, tirzepatide)
- Monitor blood glucose closely if combining with insulin-sensitizing compounds
- BPC-157 may be run concurrently for gastric protection at 250-500mcg/day
- Ensure adequate protein intake to preserve lean mass during caloric deficit
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Metabolic Panel | Fasting glucose, HbA1c, fasting insulin, HOMA-IR | Baseline, Week 4, 8, 12 |
| Lipid Panel | Total cholesterol, LDL, HDL, triglycerides | Baseline, Week 8, 16 |
| Liver Function | ALT, AST, GGT, bilirubin | Baseline, Week 8 |
| Kidney Function | BUN, creatinine, eGFR | Baseline, Week 8 |
| Pancreatic | Amylase, lipase | Baseline, Week 4, 8 |
| Thyroid | TSH, free T3, free T4 | Baseline, Week 12 |
| Inflammatory | hs-CRP, ESR | Baseline, Week 12 |
Related Tools & Resources
📖 Encyclopedia Article
Semaglutide — Complete Research Guide
Mechanism of action, clinical evidence, pharmacokinetics, regulatory status & references
Read Article →
Free Functional Assessment
AI-powered root cause analysis & care plan
Start Free
Paid partnership · Learn more